Navigation

SHIRE

From Employee Ownership Index
Jump to: navigation, search
Company details
For a description of the terms used in this table, please see the help page.
Name: SHIRE
Ticker: SHP
Sector: Pharmaceuticals
Index: 3%
Date joined: 25-Mar-08
EO %: 3.5
Accounts: Dec-12
Revenue (£m): 3020.0
Employees: 5370
Website: www.shire.com
Ownership Attributes
Employees - individually %:
Employees - through a trust %:
Directors %: 0.1%
External shareholders %:
SAYE (Yes/No): Yes
SIP (Yes/No):
CSOP (Yes/No):
EMI (Yes/No):

Company description

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company's products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). In March 2013, it announced the acquisition Of Premacure AB.

Employee ownership description

Annual report: Employee share ownership is an important means to support alignment of employee interests with those of shareholders

Personal tools
Views